Next-generation DNA sequencing technology has dramatically advanced clinical oncology
through the identification of therapeutic targets and molecular biomarkers, leading to the …

Circulating tumor DNA (ctDNA) minimal residual disease (MRD) is a powerful biomarker
with the potential to improve survival outcomes for non–small-cell lung cancer (NSCLC) …

One of the great challenges in therapeutic oncology is determining who might achieve
survival benefits from a particular therapy. Studies on longitudinal circulating tumor DNA …

Background Liquid biopsy (LB) is a rapidly evolving diagnostic tool for precision oncology
that has recently found its way into routine practice as an adjunct to tissue biopsy (TB). The …

Liquid biopsies using cell-free circulating tumor DNA (ctDNA) are being used frequently in
both research and clinical settings. ctDNA can be used to identify actionable mutations to …

Next-generation sequencing (NGS) technologies are high-throughput methods for DNA
sequencing and have become a widely adopted tool in cancer research. The sheer amount …

PURPOSE Immune checkpoint inhibitors (ICIs) are increasingly being used in non–small-
cell lung cancer (NSCLC), yet biomarkers predicting their benefit are lacking. We evaluated …

PURPOSE Identification of predictors for overall survival (OS) allows timely detection of
clinical efficacy signals and therefore facilitates treatment decisions. We assessed the …

PURPOSE We hypothesized that circulating tumor DNA (ctDNA) molecular residual disease
(MRD) analysis without prior mutational knowledge could be performed after neoadjuvant …

Clonal hematopoiesis of indeterminate potential (CHIP) is a common age-related
phenomenon in which hematopoietic stem cells acquire mutations in a select set of genes …